Press Release
09.10 EEST / 08.10 CEST
Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit
Controlling the viscosity and aggregation of protein-based solutions is important for pharmaceutical formulators. Because injection volume is limited by the device, therapeutic protein formulations which are to be delivered via intramuscular or intravenous injection need to be highly concentrated. At protein concentrations greater than 200 mg*mL-1 however, viscosity increases to significantly higher than 20 cP (centipoise) to quickly exceed the maximum 40 cP viscosity deemed acceptable for a conventional subcutaneous injection.
The data support the potential of Nanoform's patented biologics platform to achieve high protein concentrations in suspension formulations that are suitable for subcutaneous injection, as shown by results of syringeability and injectability studies.
Also on
Through using nanocrystalline formulations of new drugs, and reformulating already-marketed ASD products,
Nanoform's patented controlled expansion of supercritical solutions (CESS®️) technology allows the production of particles as small as 50 nanometers, and of different shape and crystallinity, increasing the dissolution rate and helping to create more patient centric dosage forms.
The 15th Global Drug Delivery & Formulation Summit runs from
For more information on the summit visit: nanoform.com/events, and to arrange a meeting with
For further information, please contact:
Christian.jones@nanoform.com / +44 (0)7804 474 771
hvh@nanoform.com / +46 (0)7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended
http://publish.ne.cision.com//Release/ViewReleaseHtml/FE79F00C023C2B43E0C856B0705FC7D6
https://mb.cision.com/Main/18905/3974380/2781550.pdf
(c) 2024 Cision. All rights reserved., source